CD19-ku-daweenta CAR T-cell, CD22 CAR T, Lymphoma-ka weyn ee B-cell, Matthew J. Frank, NCT04088890
Heerarka sare ee CR waxaa ka adkaaday CD22-ku-daweynta CAR T-Cell ee ka dhanka ah soo noqoshada CD19 ee LBCL
Bishii Febraayo 2023, tijaabada wajiga 1 ee hal machad waxay ogaatay inay badbaado tahay oo ay suurtagal tahay dadka qaba lymfoma weyn ee B-cell (LBCL) inay isticmaalaan daawaynta T-cell ee CD22-ku hagaya.
ASTCT, CIBMTR, Lymphoma-ka weyn ee B-cell, Matthew Frank, Miltenyi Biotec, Stanford University
Bartilmaameedka daawaynta cusub ee loogu talagalay bukaanada lymfoma ee soo noqda ka dib daawaynta CAR-T
Feb 2023: Natiijooyinka tijaabada ayaa muujiyay in daawaynta cusub ee antigen antigen therapy ay keentay jawaab celin dadka qaangaarka ah ee leh lymphoma weyn ee B-cell kuwaas oo dib u soo noqday ka hor CAR-T. Sida laga soo xigtay stati..
Breyanzi, Juno Therapeutics, Lymphoma-ka weyn ee B-cell, LBCL, beddesho
Lisocabtagene maraleucel waxa u ansixisay FDA daawaynta safka labaad ee lymfoma B-cell weyn
Luulyo 2022: Lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) waxaa ansixiyay Maamulka Cuntada iyo Dawooyinka ee bukaanada qaangaarka ah ee qaba lymphoma weyn ee B-cell (LBCL) kuwaas oo qaba cudurka refractory ee chemoi-ka koowaad.
Carteyva, Daawooyinka JW, Lymphoma-ka weyn ee B-cell, qanjiro, NMPA, relmacabtagene autoleucel
JW Therapeutics' IND waxaa u fasaxay Shiinaha NMPA daawaynta CAR T-cell ee lymphoma weyn ee B-Cell
Maamulka Alaabada Caafimaadka Qaranka ee Shiinaha (NMPA) ayaa ansixiyay JW Therapeutics 'daawaynta cusub ee baadhista (IND) ee loogu talagalay tijaabada caafimaad ee muhiimka ah ee Carteyva (relmacabtagene autoleucel) ee dadka leh khadka labaad ee Bc.
Hal qayb oo ka mid ah ADC Therapeutics SA, wakiilka alkylating isku xidh, Kahortaga CD19 ee jiheeye, Kalasaarka ballaaran ee unugyada unugyada 'B-cell lymphoma', DLBCL, lymphoma-B-unug-heer sare ah, Lymphoma-ka weyn ee B-cell, Loncastuximab tesirine-lpyl, Zynlonta
FDA waxay oggolaatay loncastuximab tesirine-lpyl oo la dedejiyey oggolaanshaha lymphoma-ka weyn ee B
Ogosto 2021: FDA waxay siisay loncastuximab tesirine-lpyl (Zynlonta, ADC Therapeutics SA), antibody-CD-directed antibody iyo alkylating conjugate, ansixinta dardargelinta bukaanada qaangaarka ah